Adaptive Biotechnologies Shares Outstanding 2018-2021 | ADPT

Adaptive Biotechnologies shares outstanding history from 2018 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Adaptive Biotechnologies shares outstanding for the quarter ending June 30, 2021 were 0.140B, a 10.19% increase year-over-year.
  • Adaptive Biotechnologies 2020 shares outstanding were 0.131B, a 89.71% increase from 2019.
  • Adaptive Biotechnologies 2019 shares outstanding were 0.069B, a 447.62% increase from 2018.
  • Adaptive Biotechnologies 2018 shares outstanding were 0.013B, a 3.55% increase from 2017.
Adaptive Biotechnologies Annual Shares Outstanding
(Millions of Shares)
2020 131
2019 69
2018 13
2017 12
Adaptive Biotechnologies Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 140
2021-03-31 139
2020-12-31 131
2020-09-30 134
2020-06-30 127
2020-03-31 126
2019-12-31 69
2019-09-30 124
2019-06-30 13
2019-03-31 13
2018-12-31
2018-09-30 13
2018-06-30 12
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.521B $0.098B
Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71